Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Assess the Efficacy and Safety of XC221 in Patients With COVID-19

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04487574
Recruitment Status : Completed
First Posted : July 27, 2020
Last Update Posted : November 13, 2020
Sponsor:
Information provided by (Responsible Party):
RSV Therapeutics LLC

Tracking Information
First Submitted Date  ICMJE July 22, 2020
First Posted Date  ICMJE July 27, 2020
Last Update Posted Date November 13, 2020
Actual Study Start Date  ICMJE July 25, 2020
Actual Primary Completion Date October 29, 2020   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: July 24, 2020)
Patient rate with a transition to category 3 or lower according to the WHO scale by Day 14 after the beginning of drug administration. [ Time Frame: Day 1 - Day 14 ]
The scale of the patient's clinical condition, proposed by the WHO, will be used to assess the severity of patient general condition. Ranges for patient's clinical condition: 0 points (no infection) - 8 points (death).
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: July 24, 2020)
  • Time till clinical improvement, which is described by presence of all of the following factors during 48 hours in a row. [ Time Frame: Day 1 - Day 28 ]
    • Body temperature ≤ 37.5°C without using NSAIDs and / or paracetamol;
    • RR ≤ 22 / min without oxygen therapy;
    • SpO2 ≥ 95% without oxygen therapy.
  • Patient rate with clinical improvement by day 2-28. Presence of all of the following factors during 48 hours in a row. [ Time Frame: Day 1 - Day 28 ]
    • Body temperature ≤ 37.5°C without using NSAIDs and / or paracetamol;
    • RR ≤ 22 / min without oxygen therapy;
    • SpO2 ≥ 95% without oxygen therapy.
  • Patient rate with a negative test result for SARS-CoV-2 by Day 7±1, 15±1, 21 ±1 and 28 ± 1. [ Time Frame: Day 1 - Day 28 ]
  • Duration of hospitalization. [ Time Frame: Day 1 - Day 28 ]
  • Patient rate transferred to the intensive care unit (ICU) during hospitalization. [ Time Frame: Day 1 - Day 28 ]
  • Duration of ICU stay. [ Time Frame: Day 1 - Day 28 ]
  • Patient rate with ARDS during hospitalization. [ Time Frame: Day 1 - Day 28 ]
  • Presence of a fatal outcome. [ Time Frame: Day 1 - Day 28 ]
  • Patient rate requiring oxygen therapy by Day 2-28. [ Time Frame: Day 1 - Day 28 ]
  • Patient rate requiring high-flow oxygen therapy by Day 2-28. [ Time Frame: Day 1 - Day 28 ]
  • Patient rate requiring non-invasive ventilation by Day 2-28. [ Time Frame: Day 1 - Day 28 ]
  • Patient rate requiring invasive ventilation by Day 2-28. [ Time Frame: Day 1 - Day 28 ]
  • Patient rate requiring extracorporeal membrane oxygenation (EMO) by Day 2-28. [ Time Frame: Day 1 - Day 28 ]
  • The total duration of oxygen therapy by the last day of hospitalization. [ Time Frame: Day 1 - Day 28 ]
  • The total duration of high-flow oxygen therapy by the last day of hospitalization. [ Time Frame: Day 1 - Day 28 ]
  • The total duration of non-invasive ventilation by the last day of hospitalization. [ Time Frame: Day 1 - Day 28 ]
  • The total duration of invasive ventilation of lungs by the last day of hospitalization. [ Time Frame: Day 1 - Day 28 ]
  • The total duration of EMO by the last day of hospitalization. [ Time Frame: Day 1 - Day 28 ]
  • Patient rate with Sp02 > 95% by Day 2-28. [ Time Frame: Day 1 - Day 28 ]
  • Average alteration of Sp02 by Day 2-28 from baseline. [ Time Frame: Day 1 - Day 28 ]
  • Average time to reach SpO2 ≥ 95%. [ Time Frame: Day 1 - Day 28 ]
  • Patient rate with RR < 22 / min by Day 2-28. [ Time Frame: Day 1 - Day 28 ]
  • Average alteration in RR by Day 2-28 from baseline. [ Time Frame: Day 1 - Day 28 ]
  • Average time to reach RR ≤ 22 / min. [ Time Frame: Day 1 - Day 28 ]
  • Patient rate with body temperature < 37.5°C by Day 2-28. [ Time Frame: Day 1 - Day 28 ]
  • Average alteration in body temperature by Day 2-28 from baseline. [ Time Frame: Day 1 - Day 28 ]
  • Average time until the patient reaches a body temperature of ≤37.5°C. [ Time Frame: Day 1 - Day 28 ]
  • Patient rate with CT-1 according to CT data by Day 2-28. [ Time Frame: Day 1 - Day 28 ]
  • Average alteration in CT data by 1 point in terms of severity (CT-1, CT-2, CT-3, CT-4) by Day 7, 10, 15, 18, 21 and 28 compared to the baseline value. [ Time Frame: Day 1 - Day 28 ]
  • Average time to reach CT-1 according to CT data. [ Time Frame: Day 1 - Day 28 ]
  • Patient rate with a score < 2 according to the Daytime and Nighttime Cough Scale by Day 2-28. [ Time Frame: Day 1 - Day 28 ]
    The Daytime and Nighttime Cough Scale will be used to assess the dynamics of cough during the study. Ranges for assess: 0 points (no cough) - 6 points (severe cough that makes daytime activity impossible).
  • Mean change in Daytime and Nighttime Cough scores by Day 2-28 from baseline. [ Time Frame: Day 1 - Day 28 ]
    The Daytime and Nighttime Cough Scale will be used to assess the dynamics of cough during the study. Ranges for assess: 0 points (no cough) - 6 points (severe cough that makes daytime activity impossible).
  • Average time to reach < 2 points when assessed according to the Daytime and Nighttime Cough Scale. [ Time Frame: Day 1 - Day 28 ]
    The Daytime and Nighttime Cough Scale will be used to assess the dynamics of cough during the study. Ranges for assess: 0 points (no cough) - 6 points (severe cough that makes daytime activity impossible).
  • Patient rate with a score < 1 for each symptom (general fatigue, chest congestion, sore throat, decreased sense of smell and taste, nasal congestion) according to a 4-point scale by Day 2-28. [ Time Frame: Day 1 - Day 28 ]
    The Symptom Rating Scale will be used to assess the individuals' subjective ratings the severity of 6 symptoms of COVID-19. Ranges for each symptom: 0 points (no symptoms) - 3 points (the most severe). Total score (ranges from 0 to 18 points) is a sum of points for each symptom.
  • Average change in score for each symptom (general fatigue, chest congestion, sore throat, decreased sense of smell and taste, nasal congestion) according to a 4-point scale by Day 2-28 from baseline. [ Time Frame: Day 1 - Day 28 ]
    The Symptom Rating Scale will be used to assess the individuals' subjective ratings the severity of 6 symptoms of COVID-19. Ranges for each symptom: 0 points (no symptoms) - 3 points (the most severe). Total score (ranges from 0 to 18 points) is a sum of points for each symptom.
  • Average time to reach a score of < 1 for each symptom (general fatigue, feeling of congestion in the chest, sore throat, decreased sense of smell and taste, nasal congestion) according to a 4-point scale. [ Time Frame: Day 1 - Day 28 ]
    The Symptom Rating Scale will be used to assess the individuals' subjective ratings the severity of 6 symptoms of COVID-19. Ranges for each symptom: 0 points (no symptoms) - 3 points (the most severe). Total score (ranges from 0 to 18 points) is a sum of points for each symptom.
  • Patient rate with a transition decrease to category 3 or lower according to the WHO scale by Day 2-13 and Day 15-28. [ Time Frame: Day 1 - Day 28 ]
    The scale of the patient's clinical condition, proposed by the WHO, will be used to assess the severity of patient general condition. Ranges for patient's clinical condition: 0 points (no infection) - 8 points (death).
  • Mean WHO grade change by Day 2-28 from baseline. [ Time Frame: Day 1 - Day 28 ]
    The scale of the patient's clinical condition, proposed by the WHO, will be used to assess the severity of patient general condition. Ranges for patient's clinical condition: 0 points (no infection) - 8 points (death).
  • Average time to reach the 3rd category or below according to the WHO scale. [ Time Frame: Day 1 - Day 28 ]
    The scale of the patient's clinical condition, proposed by the WHO, will be used to assess the severity of patient general condition. Ranges for patient's clinical condition: 0 points (no infection) - 8 points (death).
  • Patient rate with a NEWS score < 2 by Day 2-28. [ Time Frame: Day 1 - Day 28 ]
    Parameters will be assessed according to the National Early Warning Score only during hospitalization. During the treatment period, the assessment will be performed 2 times a day. During the follow-up period, the assessment will be performed once a day. The worst result for each period is to be chosen.
  • Average change in NEWS score by Day 2-28 from baseline. [ Time Frame: Day 1 - Day 28 ]
    Parameters will be assessed according to the National Early Warning Score only during hospitalization. During the treatment period, the assessment will be performed 2 times a day. During the follow-up period, the assessment will be performed once a day. The worst result for each period is to be chosen.
  • Average time to reach a NEWS score ≤ 2. [ Time Frame: Day 1 - Day 28 ]
    Parameters will be assessed according to the National Early Warning Score only during hospitalization. During the treatment period, the assessment will be performed 2 times a day. During the follow-up period, the assessment will be performed once a day. The worst result for each period is to be chosen.
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures
 (submitted: July 24, 2020)
Concentration of IL-6 on Days 3 ± 1, 7 ± 1, 15 ± 1. [ Time Frame: Day 1 - Day 15 ]
(Search Outcome)
Original Other Pre-specified Outcome Measures Same as current
 
Descriptive Information
Brief Title  ICMJE A Study to Assess the Efficacy and Safety of XC221 in Patients With COVID-19
Official Title  ICMJE A Multicenter, Adaptive, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of XC221, Tablets, 100 mg in Patients With COVID-19
Brief Summary

The innovative drug XC221 100 mg tablet is designed for the treatment of COVID-19 (SARS-CoV-2 infection). A multicenter, adaptive, randomized, double-blind, placebo-controlled Phase III clinical study is aimed to assess the efficacy and safety of XC221 100 mg tablet, in COVID-19 patients during a 14-day treatment.

The primary objective of the study is to demonstrate the efficacy of XC221 100 mg tablet (200 mg daily dose) in achieving clinical improvement of COVID-19 symptoms.

The secondary objective of the study is to evaluate the safety of XC221 100 mg tablet (200 mg daily dose) in COVID-19 patients.

Detailed Description

11 Russian centers will participate in this study. The trail will consist of three periods: screening (duration not more than 1 day, it may coincide with the randomization visit and beginning of drug administration), treatment period (14 days) and follow-up period (14 ± 1 days after completion of treatment with XC221 / Placebo). The duration of participation in the study for each patient will be no more than 30 days.

118 eligible patients with confirmed COVID-19 will be randomized into two groups (Group A and Group B) in a 1:1 ratio: Group A - XC221 200 mg daily (59 patients); Group В - Placebo (59 patients).

During the treatment period (14 days), 1 tablet of XC221 / Placebo will be administered 2 times a day in addition to the standard of care (SoC) for COVID-19 according to The Temporary guidelines for the prevention, diagnosis and treatment of SARS-CoV-2 infection of the Ministry of Health of the Russian Federation (the MoH Temporary Guidelines). The follow-up period will last for 14 days.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Masking Description:
Tablets identical in terms of composition, appearance and labeling to XC221 tablets, but without active substance will be used as Placebo.
Primary Purpose: Treatment
Condition  ICMJE SARS-CoV-2 Infection
Intervention  ICMJE
  • Drug: XC221
    Participants will receive XC221 100 mg 2 times a day during 14 days
  • Drug: Placebo
    Participants will receive Placebo 2 times a day during 14 days
Study Arms  ICMJE
  • Experimental: XC221

    XC221 100 mg orally.

    1 tablet of XC221 100 mg 2 times a day during 14 days of treatment period.

    Intervention: Drug: XC221
  • Placebo Comparator: Placebo

    Placebo orally.

    1 tablet of Placebo 2 times a day during 14 days of treatment period

    Intervention: Drug: Placebo
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: July 24, 2020)
118
Original Estimated Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE October 29, 2020
Actual Primary Completion Date October 29, 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Signed Informed Consent Form.
  2. Patients of both sexes aged 18 to 75 years inclusive.
  3. Diagnosed COVID-19 based on:

    • positive laboratory tests confirming the SARS-CoV-2 presence, performed no earlier than 14 days before hospitalization. It is allowed to determine the SARS-CoV-2 by the PCR or by another method according to the MoH Temporary Guidelines; and / or
    • bilateral alterations in lungs, typical for COVID-19, according to CT scan of the chest.
  4. Patients with moderate or severe form of disease (t > 38.0°C; respiratory rate (RR) >22 / min; Sp02 <95%) not requiring non-invasive / invasive ventilation and / or high-flow oxygenation (HFNT), and / or extracorporeal membrane oxygenation (EMO) at the time of screening and randomization (based on the MoH Temporary Guidelines).
  5. Patients requiring oxygen therapy (oxygenation through a nasal cannula, a simple facemask or other similar oxygen delivery device) with a category "4" according to the WHO scale.
  6. Time from hospitalization to the first drug administration should not exceed 48 hours. This item is to be assessed only when re-evaluating the inclusion / exclusion criteria at the Randomization visit and treatment initiation.
  7. Disease duration is no more than 7 full days since the moment of appearing one or more of the symptoms below until the first dose of the drug administration:

    • temperature increase;
    • dry cough or cough with little phlegm;
    • shortness of breath;
    • myalgia;
    • fatigue;
    • feeling of congestion in the chest;
    • reduced sense of smell and / or taste.
  8. For women only: negative pregnancy test result. Pregnancy testing is not required for women of not childbearing potential (WONCBP): women who are in menopause (defined as an absence of menstruation for at least 2 years or more), or women who undergone surgical sterilization (hysterectomy, bilateral oophorectomy, tubal ligation), or women with a clinical diagnosis of "infertility". The presence of surgical sterilization and infertility should be confirmed by patient's claim or by relevant document confirming this condition.
  9. Consent to use reliable method of contraception throughout the study period.
  10. Patients who are able to understand and comply with treatment and procedures during the study.

Exclusion Criteria:

  1. Known or suspected hypersensitivity to the active substance or to excipients of the drug XC221 or placebo
  2. Known or suspected hypersensitivity to standard therapy drugs specified in The MoH Temporary Guidelines.
  3. Lactase deficiency, lactose intolerance, glucose-galactose malabsorption.
  4. Presence or suspicion of oncological diseases by the day of criteria assessment or in medical history (within the last 2 years).
  5. Presence of autoimmune diseases by the day of criteria assessment or in medical history.
  6. Neutropenia (0.5 * 10^9 /l).
  7. Exceeding the upper limit of normal for ALT and AST by 5 times or more.
  8. Thrombocytopenia 50000 / mm^3.
  9. Pregnancy.
  10. Lactation.
  11. Presence of serious lung diseases, including, but not limited to the following diseases: moderate and severe bronchial asthma, severe and extremely severe COPD, interstitial lung disease, pulmonary hypertension, pulmonary fibrosis, surgical interventions on the lungs, tuberculosis (including suspicion of tuberculosis based on the results of CT examination at screening).
  12. Patients with type 1 diabetes mellitus and / or decompensated type 2 diabetes mellitus.
  13. Heart failure, NYHA functional class III - IV.
  14. Chronic liver failure stage II (decompensated) and higher.
  15. The need of renal replacement therapy at the time of inclusion of the patient.
  16. Organ transplantation in medical history.
  17. Medical history of epilepsy or the need for anticonvulsant therapy.
  18. Major depressive disorder, anxiety, other mental disorders requiring medical correction.
  19. Acute cerebrovascular accident, stroke or transient ischemic attack within 90 days before screening.
  20. Administration of any antiviral and / or immunomodulatory drugs after the manifestation of COVID-19, with the exception of those specified in the MoH Temporary Guidelines.
  21. Any immunosuppressive therapy (including tocilizumab / sarilumab) within 90 days prior to randomization, or the need of immunosuppressive therapy at the time of randomization.
  22. Administration of systemic glucocorticosteroids within 90 days prior to randomization, or the need of systemic glucocorticosteroids at the time of randomization.
  23. Administration of vaccines against viral infections within 90 days prior to randomization.
  24. Patients receiving other experimental drugs, drugs not approved in the Russian Federation, or participating in other clinical trials within 30 days before screening.
  25. Patients abusing alcohol or psychotropic drugs and other drugs by the day of criteria assessment or during the last year.
  26. Patients with other serious, unstable, or clinically significant medical or psychological conditions that, in the opinion of the investigator, may preclude the patient's participation in the study.
  27. Expected death within 48 hours after randomization.
  28. Expected hospital discharge within 48 hours of randomization.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 75 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Russian Federation
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04487574
Other Study ID Numbers  ICMJE XC221-03-02-2020
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party RSV Therapeutics LLC
Study Sponsor  ICMJE RSV Therapeutics LLC
Collaborators  ICMJE Not Provided
Investigators  ICMJE Not Provided
PRS Account RSV Therapeutics LLC
Verification Date November 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP